Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23515067 | 0.81 | MAPT (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL24746028 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A9 | |
| SCHEMBL25065358 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23498059 | 0.80 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL23498005 | 0.80 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL24424876 | 0.79 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL20756622 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL17297739 | 0.76 | USP1 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL17664587 | 0.74 | MAPT (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL24746250 | 0.74 | SLC6A9 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | CHRNB2 1543/4885CHRNA4 1775/4885CHRNB4 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.